Compare Quest Diagnostics Inc (DGX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Quest Diagnostics Inc trades at $205.48 (market cap $22.80B), while ProShares UltraPro Short QQQ ETF trades at $37.98. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while ProShares UltraPro Short QQQ ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| DGX | SQQQ | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.02 | $97.60 |
52-Week Low | $166.42 | $36.31 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SQQQ (ProShares UltraPro Short QQQ ETF) trades at $39.95, up 5.74% ($2.17) in the last session. The ETF shows a neutral technical signal overall with bullish moving averages and neutral oscillators. Recent news highlights SQQQ's role as a tactical hedging tool against Nasdaq 100 declines, though long-term performance erosion due to daily -3x leverage remains a concern. Short interest increased 19.4% in March 2026, reflecting bearish sentiment toward tech.
Outlook: SQQQ is a high-risk, short-term instrument for hedging QQQ exposure, not a long-term investment. Opportunities exist for tactical investors during tech selloffs, but risks include volatility decay, timing challenges, and structural erosion. Investors should understand the leveraged ETF's mechanics and use it cautiously within a diversified strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
